Unveiling the hidden ocular risks of isotretinoin: a comprehensive FAERS-Based analysis.

IF 3.1 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Tao Tao, Guo Lei Du, Zhi-Jie Zhang, Zhan Yang Luo, Jia-Feng Tang, Xiang Li
{"title":"Unveiling the hidden ocular risks of isotretinoin: a comprehensive FAERS-Based analysis.","authors":"Tao Tao, Guo Lei Du, Zhi-Jie Zhang, Zhan Yang Luo, Jia-Feng Tang, Xiang Li","doi":"10.1080/14740338.2025.2505530","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>While extensive research has been conducted on isotretinoin's systemic side effects, studies focusing on its ocular side effects remain limited and often lack substantial sample sizes. To address this gap, we conducted a comprehensive investigation of isotretinoin-related ocular toxicity using data from the FAERS spanning 2004 to 2024.</p><p><strong>Methods: </strong>After excluding duplicate and incomplete records from the FAERS database, we identified 760 eye-related adverse event reports from a total of 45,258 isotretinoin-related entries. We employed the Reporting Odds Ratio (ROR) method to assess the risk of ocular problems. Additionally, we examined the onset timing of eye toxicity.</p><p><strong>Results: </strong>Among the 760 reports analyzed, dry eye emerged as the most frequently reported condition (<i>n</i> = 222), although it did not exhibit the strongest association. The ROR was observed for night blindness (ROR = 35.8, 95% CI = 29.66-43.21), indicating a significant risk. This finding underscores the need to focus on isotretinoin's impact on the retina and fundus, especially since night blindness and vision loss can manifest as early as the first day of treatment.</p><p><strong>Conclusion: </strong>These findings prompt new recommendations for safety monitoring by clinicians. However, additional clinical and fundamental research is essential to substantiate these observations and further elucidate the effects of isotretinoin on ocular health.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1-9"},"PeriodicalIF":3.1000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14740338.2025.2505530","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: While extensive research has been conducted on isotretinoin's systemic side effects, studies focusing on its ocular side effects remain limited and often lack substantial sample sizes. To address this gap, we conducted a comprehensive investigation of isotretinoin-related ocular toxicity using data from the FAERS spanning 2004 to 2024.

Methods: After excluding duplicate and incomplete records from the FAERS database, we identified 760 eye-related adverse event reports from a total of 45,258 isotretinoin-related entries. We employed the Reporting Odds Ratio (ROR) method to assess the risk of ocular problems. Additionally, we examined the onset timing of eye toxicity.

Results: Among the 760 reports analyzed, dry eye emerged as the most frequently reported condition (n = 222), although it did not exhibit the strongest association. The ROR was observed for night blindness (ROR = 35.8, 95% CI = 29.66-43.21), indicating a significant risk. This finding underscores the need to focus on isotretinoin's impact on the retina and fundus, especially since night blindness and vision loss can manifest as early as the first day of treatment.

Conclusion: These findings prompt new recommendations for safety monitoring by clinicians. However, additional clinical and fundamental research is essential to substantiate these observations and further elucidate the effects of isotretinoin on ocular health.

揭示异维甲酸隐藏的眼部风险:基于faers的综合分析。
目的:虽然对异维甲酸的全身副作用进行了广泛的研究,但对其眼部副作用的研究仍然有限,而且往往缺乏足够的样本量。为了解决这一差距,我们利用2004年至2024年FAERS的数据对异维甲酸相关的眼毒性进行了全面调查。方法:在从FAERS数据库中排除重复和不完整的记录后,我们从总共45258份异维甲酸相关条目中确定了760份与眼睛相关的不良事件报告。我们采用报告优势比(ROR)方法评估眼部问题的风险。此外,我们检查了眼毒性的发病时间。结果:在分析的760份报告中,干眼症是最常报告的疾病(n = 222),尽管它并没有表现出最强的相关性。观察夜盲症的ROR (ROR = 35.8, 95% CI = 29.66 ~ 43.21),提示存在显著风险。这一发现强调了关注异维甲酸对视网膜和眼底的影响的必要性,特别是因为夜盲症和视力丧失可能早在治疗的第一天就表现出来。结论:我们的研究已经确定了与异维甲酸相关的各种眼部首选术语(PTs),强调了与视网膜效应的重要联系。值得注意的是,一些人在短期使用异维甲酸后报告失明和夜盲症。这些发现促使临床医生对安全监测提出新的建议。然而,需要更多的临床和基础研究来证实这些观察结果,并进一步阐明异维甲酸对眼健康的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.90
自引率
3.20%
发文量
97
审稿时长
6-12 weeks
期刊介绍: Expert Opinion on Drug Safety ranks #62 of 216 in the Pharmacology & Pharmacy category in the 2008 ISI Journal Citation Reports. Expert Opinion on Drug Safety (ISSN 1474-0338 [print], 1744-764X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of drug safety and original papers on the clinical implications of drug treatment safety issues, providing expert opinion on the scope for future development.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信